Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)

Rhea-AI Summary

Tyra Biosciences (Nasdaq: TYRA) announced three abstracts for presentation at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) in Barcelona, Spain, from October 23-25, 2024. The presentations include:

1. A late-breaking oral presentation on the preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors with activating FGFR3 mutations/fusions (SURF301).

2. A poster on the preliminary pharmacokinetic and pharmacodynamic analysis of TYRA-300 from the SURF301 study.

3. A poster on the multicenter, open-label Phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 gene alterations (SURF301).

The abstracts are embargoed until 00.01 hrs CEST on Friday, October 25, 2024.

Positive

• Selection of three abstracts for presentation at a major cancer therapeutics symposium
• Late-breaking oral presentation slot for TYRA-300 preliminary safety and anti-tumor activity data
• Ongoing clinical trials (SURF301) for TYRA-300 in advanced solid tumors with FGFR3 mutations/fusions

Negative

• None.

News Market Reaction

+4.58%

1 alert

+4.58% News Effect

On the day this news was published, TYRA gained 4.58%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

-TYRA will also present two posters on PK/PD of TYRA-300 and a Trials-in-Progress from SURF301 -

CARLSBAD, Calif., Oct. 11, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the selection of three abstracts for presentation, including a late-breaking oral presentation, at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024), taking place October 23-25, 2024, in Barcelona, Spain. 

Details of the presentations are below:

Title: "Preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors with activating FGFR3 mutations/fusions (SURF301)"

Session: Late Breaking Abstracts and Proffered Papers: Novel discoveries in drug development
Date: Friday, October 25, 2024
Time: 15:36 - 15:48 hrs CEST
Abstract #: LBA500

Title: "TYRA-300, an oral, FGFR3-selective inhibitor: Preliminary pharmacokinetic and pharmacodynamic analysis from SURF301, the multicenter open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations"

Abstract #: 72
Poster #: PB060

Title: "A Multicenter, Open-label Phase 1/2 Study of TYRA 300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF301)"

Abstract #: 35
Poster #: PB023

The abstracts related to the presentations are under embargo until 00.01 hrs CEST on Friday, October 25, 2024.

About Tyra Biosciences

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in Carlsbad, CA. 

For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.

Contact:

Amy Conrad
aconrad@tyra.bio

View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-announces-late-breaking-oral-presentation-on-preliminary-safety-and-anti-tumor-activity-of-tyra-300-from-surf301-at-the-36th-eortc-nci-aacr-symposium-on-molecular-targets-and-cancer-therapeutics-ena-2024-302273982.html

SOURCE Tyra Biosciences

FAQ

What is TYRA-300 and what is it being studied for?

TYRA-300 is a highly selective FGFR3 inhibitor being studied in the SURF301 trial for advanced solid tumors with activating FGFR3 mutations/fusions, including advanced urothelial carcinoma.

When and where will Tyra Biosciences (TYRA) present its TYRA-300 data at ENA 2024?

Tyra Biosciences will present TYRA-300 data at the 36th EORTC-NCI-AACR Symposium (ENA 2024) in Barcelona, Spain, from October 23-25, 2024. The late-breaking oral presentation is scheduled for October 25, 2024, at 15:36 - 15:48 hrs CEST.

How many abstracts will Tyra Biosciences (TYRA) present at ENA 2024?

Tyra Biosciences will present three abstracts at ENA 2024, including one late-breaking oral presentation and two poster presentations.

What is the SURF301 study mentioned in Tyra Biosciences' (TYRA) presentations?

SURF301 is a multicenter, open-label Phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 gene alterations.